Pesticide Exposure and Risk for Parkinsons Disease
Ann Neurol 60:197-203, Ascherio,A.,et al, 2006
A Randomized Trial of Deep-Brain Stimulation for Parkinsons Disease
NEJM 355:896-908, Deuschl,G.,et al, 2006
What is the Risk of Developing Parkinsonism Following Neuroleptic Use?
Neurol 66:941-943, Noyes,K.,et al, 2006
Nonsteroidal Anti-Inflammatory Drugs and the Incidence of Parkinson Disease
Neurol 66:1097-1099, Hernan,M.A.,et al, 2006
Practice Parameter: Evaluation and Treatment of Depression, Psychosis, and Dementia in Parkinson Disease (An Evidence-Based Review)
Neurol 66:996-1002, Miyasaki,J.M.,et al, 2006
Practice Parameter: Treatment of Parkinson Disease with Motor Fluctuations and Dyskinesia (An Evidence-Based Review)
Neurol 66:983-995, Pahwa,R.,et al, 2006
Suicide After Deep Brain Stimulation of the Internal Globus Pallidus for Dystonia
Neurol 66:142-143, Foncke,E.M.J.,et al, 2006
Panic and Fear Induced by Deep Brain Stimulation
JNNP 77:410-412, Shapira,HN.A.,et al, 2006
Familial Dopa-Responsive Cervical Dystonia
Neurol 66:599-601, Schneider,S.A.,et al, 2006
Hiccups Associated with Dopamine Agonists in Parkinson Disease
Neurol 66:774-775, Sharma,P.,et al, 2006
Diffusion-Weighted Magnetic Resonance Imaging in the Syndrome of Acute Bilateral Basal Ganglia Lesions in Diabetic Uremia
Mov Disord 21:1267-1270, Kim, T.,et al, 2006
Phenotypic Spectrum Associated with Mutations of the Mitochondrial Polymerase y Gene
Brain 129:1674-1684, Horvath, R.,et al, 2006
Mitochondrial DNA Polymerase-y and Human Disease
Hum Mol Genet 15:R244-R252, Hudson, G.,et al, 2006
Progressive Myoclonic Epilepsies: A Review of Genetic and Therapeutic Aspects
Lancet Neurol 4:239-248, Shahwan, A., et al, 2005
Modafinil for Daytime Somnolence in Parkinsons Disease: Double Blind, Placebo Controlled Parallel Trial
JNNP 76:1636-1639, Ondo,W.G.,et al, 2005
Two Patients With COMT Inhibitor-Induced Hepatic Dysfunction and UGT1A9 Genetic Polymorphism
Neurol 65:1820-1822, Martignoni,E.,et al, 2005
Cluster Headache:Pathogenesis,Diagnosis, and Management
Lancet 366:843-855, May,A., 2005
Spontaneous CSF Leak Treated with Percutaneous CT-Guided Fibrin Glue
Neurol 64:1818-1819, Gladstone,J.P.,et al, 2005
[99mTc]TRODAT-1 SPECT Imaging Correlates with Odor Identification in Early Parkinson Disease
Neurol 64:1716-1720, Siderowf,A.,et al, 2005
Science and Ethics of Sham Surgery, A Survey of Parkinson Disease Clinical Researchers
Arch Neurol 62:1357-1360,1343, Kim,S.Y.H.,et al, 2005
Neurologic Spectrum of Chronic Liver Failure and Basal Ganglia T1 Hyperintensity on Magnetic Resonance Imaging, Probably Manganese Neurotoxicity
Arch Neurol 62:1385-1390, Klos,K.J.,et al, 2005
Pathological Gambling Caused by Drugs Used to Treat Parkinson Disease
Arch Neurol 62:1377-1381, Dodd,M.L.,et al, 2005
Neuropathology of Dementia in Parkinsons Disease: A Prospective, Community-Based Study
Ann Neurol 58:773-776,663, Aarsland,D.,et al, 2005
Cabergoline-Related Severe Restrictive Mitral Regurgitation
NEJM 353:1974-1975, Rosen,C.J., 2005
Occupation and Parkinsonism in Three Movement Disorders Clinics
Neurol 65:1430-1435, Goldman,S.M.,et al, 2005
Excessive Daytime Sleepiness and Subsequent Development of Parkinson Disease
Neurol 65:1442-1446, Abbott,R.D.,et al, 2005
Bilateral Deep-Brain Stimulation of the Globus Pallidus in Primary Generalized Dystonia
NEJM 352:5 459-467, 498, Vidailhet, M., et al, 2005
Quantatative Assessment of Driving Performance in Parkinson's Disease
JNNP 76:176-180, 159, Wood, J.M., et al, 2005
Genetic Screening for a Single Common LRRK2 Mutation in Familial Parkinson's Disease
Lancet 365:410-412, Nichols, W.C., et al, 2005
Pallidal vs Subthalamic Nucleus Deep Brain Stimulation in Parkinson Disease
Arch Neurol 62:554-560,533, Anderson,V.C.,et al, 2005
Pallidal Stimulation Improves Pantothenate Kinase-Associated Neurodegeneration
Ann Neurol 57:738-741,613, Castelnau,P.,et al, 2005
Tourettes Syndrome and Deep Brain Stimulation
JNNP 76:992-995, Houeto,J.L.,et al, 2005
Donepezil for Dementia in Parkinsons Disease: A Randomised, Double Blind, Placebo Controlled, Crossover Study
JNNP 76:934-939,903, Ravina,B.,et al, 2005
Vertebrobasilar Disease
NEJM 352:2618-2626, Savitz,S.I.&Caplan,L.R., 2005
Searching for a Relationship Between Manganese and Welding and Parkinsons Disease
Neurol 64:2021-2028, 2001, Jankovic,J., 2005
Neurologic Manifestations in Welders with Pallidal MRI T1 Hyperintensity
Neurol 64:2033-2039,2001, Josephs,K.A.,et al, 2005
New and Reliable MRI Diagnosis for Progressive Supranuclear Palsy
Neurol 64:2050-2055, Oba,H.,et al, 2005
Pleuropulmonary Fibrosis After Long-term Treatment With the Dopamine Agonist Pergolide for Parkinson Disease
Arch Neurol 62:1290-1295, Tintner,R.,et al, 2005
Sudden Uncontrollable Somnolence and Medication Use in Parkinson Disease
Arch Neurol 62:1242-1248, Avorn,J.,et al, 2005
Camptocormia
Neurol 65:355-359, Azher,S.N. &Jankovic,J., 2005
Initial Diagnoses Given to Persons with the Fragile X Associated Tremor/Ataxia Syndrome (FXTAS)
Neurol 65:299-301, Hall,D.A.,et al, 2005
The role of radiotracer imaging in Parkinson disease
Neurol 64:208-215, Ravina, B., et al, 2005
Amorphine-induced eosinophilic panniculitis and hypereosinophilia in Parkinson disease
Neurol 64:392-393, Pot, C., et al, 2005
Neurocardiogenic Syncope
NEJM 352:1004-1010, Grubb, B.P., 2005
The Serotonin Syndrome
NEMJ 352:1112-20, Boyer, E.W. & Shannon, M., 2005
Rivastigmine for Dementia Associated with Parkinson's Disease
NEJM 351:2509-2518,2547, Emre,M.,et al, 2004
Suicide After Successful Deep Brain Stimulation for Movement Disorders
Neurol 63:2170-2172, Burkhard,P.R.,et al, 2004
Correlation Between Antemortem Magnetic Resonance Imaging Findings and Pathologically Confirmed Corticobasal Degeneration
Arch Neurol 61:1881-1884, Josephs,K.A.,et al, 2004
Parenteral Metoclopramide for Acute Migraine: Meta-Analysis of Randomised Controlled Trials
BMJ 329:1369-1372, Colman,I.,et al, 2004
Effective Cabergoline Treatment in Idiopathic Restless Legs Syndrome
Neurol 63:2272-2279, Stiasny-Kolster,K.,et al, 2004